Recognize Steroid-Refractory GVHD and Escalate to Ruxolitinib

Recognize Steroid-Refractory GVHD and Escalate to Ruxolitinib

A 15-minute microlearning on identifying steroid-refractory acute GVHD using consensus criteria, initiating ruxolitinib as second-line therapy, considering remestemcel-L-rknd as a pediatric alternative, and recognizing that no preferred third-line agent exists.

Price
Free
Provider
IQ Apparatus
Release date
August 17, 2026
Expires
July 22, 2027
Start activity

Credits

Learning objectives

Upon completion, participants should be able to:

  1. Apply current aGVHD staging, grading, and treatment-response criteria to assess disease severity and identify steroid-refractory disease.
  2. Evaluate clinical and biomarker-based risk-stratification tools to support aGVHD prognostication while recognizing their limitations in guiding routine treatment decisions.
  3. Determine when treatment escalation is appropriate for patients with steroid-refractory aGVHD based on current criteria and guideline recommendations.

Faculty